Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.41 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6670026 | 0.87 | POLA1 (0.49) | POLA1KCNH2MLLT1ALDH1A1TSHR | |
| SCHEMBL6694397 | 0.85 | POLA1 (0.47) | POLA1KCNH2ALDH1A1TSHRENPP2 | |
| SCHEMBL6668085 | 0.85 | POLA1 (0.42) | POLA1KCNH2MLLT1ALDH1A1TSHR | |
| SCHEMBL6666948 | 0.84 | POLA1 (0.45) | POLA1KCNH2MLLT1ALDH1A1TSHR | |
| SCHEMBL6667709 | 0.83 | POLA1 (0.49) | POLA1KCNH2MLLT1ALDH1A1TSHR | |
| SCHEMBL6667336 | 0.83 | KCNH2 (0.48) | POLA1KCNH2MLLT1ALDH1A1TSHR | |
| SCHEMBL6667294 | 0.83 | POLA1 (0.44) | POLA1KCNH2MLLT1ALDH1A1TSHR | |
| SCHEMBL6668827 | 0.82 | POLA1 (0.48) | POLA1KCNH2MLLT1ALDH1A1TSHR | |
| SCHEMBL6670027 | 0.82 | POLA1 (0.48) | POLA1KCNH2MLLT1ALDH1A1TSHR | |
| SCHEMBL6698559 | 0.81 | POLA1 (0.47) | POLA1KCNH2MLLT1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-04-08 | — | — | US | claimed |
| WO-2004019940-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | claimed |
| EP-1265872-A1 | 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| US-6458788-B1 | VIRICIDES; HERPES VIRUS | PHARMACIA & UPJOHN COMPANY | 2002-10-01 | — | — | US | claimed |
| US-20020042397-A1 | 4-hydroxycinnoline-3-carboxyamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | claimed |
| WO-2001081318-A1 | 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-11-01 | — | — | WO | claimed |
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-04-08 | — | — | US | disclosed |
| WO-2004019940-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | disclosed |
| EP-1265872-A1 | 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6458788-B1 | VIRICIDES; HERPES VIRUS | PHARMACIA & UPJOHN COMPANY | 2002-10-01 | — | — | US | disclosed |
| US-20020042397-A1 | 4-hydroxycinnoline-3-carboxyamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
| WO-2001081318-A1 | 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042397-A1 | 4-hydroxycinnoline-3-carboxyamides as antiviral agents | HAVCR2, ZC3HAV1, HCFC1 | POLA1 2405/4885KCNH2 1186/4885MLLT1 4192/4885 |
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, MSR1, NR1H2 | POLA1 2850/4885KCNH2 4046/4885MLLT1 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.